Merck Q3 Earnings Beat Expectations on Keytruda Demand
Merck reported stronger-than-expected third-quarter earnings driven by high demand for its cancer drug Keytruda and Gardasil vaccine. The drugmaker also raised its full-year financial forecasts.
Xurve View
Insights:
Xurve View
Merck & Co. Inc. reported third-quarter revenue of $18.1 billion Thursday morning, beating expectations on strong cancer drug demand. The United States drugmaker's performance topped the $17.3 billion average estimate from Wall Street analysts. The results highlight robust sales for core immunotherapy and vaccine products despite upcoming patent expirations.